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Abstract
Ovarian cancer is the most common cause of death from gynecological cancers in the Western
world. There are many genetic and environmental factors which can influence a woman's risk of
getting ovarian cancer. A strong family history of breast or ovarian cancer is definitely one of the
most important and best-defined epidemiological risk factors. This review evaluates current
knowledge of hereditary ovarian cancer. Histologic, cytologic and molecular studies on the ovarian
surface epithelium (OSE), which is the origin of ovarian epithelial carcinomas, from women with a
strong family history for ovarian carcinomas or with a mutation in one of the two known cancer
susceptibility genes – BRCA1 and BRCA2, provide a background to facilitate understanding of the
early changes in ovarian carcinogenesis. This overview is followed by a discussion of recent
hypotheses and research on two questions. First, is there a mutational hotspot of BRCA mutation
for ovarian cancer? Second, why do mutations in BRCA1 and BRCA2, which are ubiquitously
expressed genes that participate in general cellular activities, lead preferentially to breast and
ovarian cancer?
Introduction
Ovarian surface epithelium (OSE)-derived ovarian carci-
noma is the most lethal gynecological malignancy in
North America. 5–10% of epithelial ovarian cancer
involves strong family histories. Thus, the familial compo-
nent is one of the most important and best-defined risk
factors for ovarian cancer. A woman's lifetime risk for
ovarian cancer is 1.4% but is estimated to be 15–60% for
women with a strong family history and/or those who
inherited a germline mutation in certain cancer suscepti-
bility genes [1,2] (see below), suggesting that this
increased risk has a genetic component. A strong family
history refers to those having two or more first-degree rel-
atives (parents, siblings and children) diagnosed with
breast or ovarian cancer, and in some circumstances with
features of a type of bowel cancer (hereditary non-polypo-
sis colon cancer, HNPCC, also called Lynch Syndrome II),
at age 45 or younger. There are at least three types of fam-
ily history of ovarian cancer indicative of a putative auto-
somal dominantly inherited cancer susceptibility
syndrome: hereditary site-specific ovarian cancer, Lynch
syndrome II and hereditary breast/ovarian carcinoma. The
discovery of DNA mismatch repair genes such as MSH2
and MLH1 for the Lynch Syndrome II [3–5], and the iden-
tification of BRCA1 and BRCA2 tumor suppressor pro-
teins in hereditary breast/ovarian cancer syndrome
[2,6,7], have advanced our knowledge on the etiology of
familial ovarian cancer. Mutations in the BRCA1 and
BRCA2 genes, in particular, account for as much as 90%
of cancers in women with familial ovarian cancer histories
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a BRCA1 or BRCA2 mutation is estimated to be as high as
60–70% [1]. The majority of BRCA1 or BRCA2 mutations
are presumed to lead to premature protein truncations as
a result of frameshift deletions/insertions or nonsense
mutations and alter the functions of BRCA protein.
Whereas the functions of the BRCA1 and BRCA2 proteins
have yet to be fully elucidated, BRCA genes are believed to
be tumor suppressor genes, where they inhibit the growth
of cancer cells through their roles in the maintenance of
genome integrity, DNA repair, cell cycle control and apop-
tosis [8].
There is embryological and in vitro evidence that ovarian
surface epithelium (OSE) is the origin of ovarian epithe-
lial carcinomas [9]. OSE is a simple mesothelium that
overlies the surface of the ovary. It is important to note
that the adult OSE and the Mullerian epithelia arise from
a common embryonic origin, the celomic epithelium. In
early development, OSE cells form part of the celomic epi-
thelium and the celomic epithelium adjacent to the pre-
sumptive gonads invaginates to give rise to the Mullerian
ducts, i.e. the primordia for the epithelia of the oviduct,
endometrium and endocervix. The relevance of this close
developmental relationship between the OSE and the
Mullerian epithelia could explain the frequent acquisition
of architectural and functional characteristics of the Mul-
lerian epithelia during neoplastic progression of OSE and
the similarities between OSE-derived carcinomas and
Mullerian epithelial malignancies. OSE cells from ovaries
of women with strong familial history of ovarian cancer
frequently undergo Mullerian metaplasia in adult life.
This will become apparent later in this review.
Is there a premalignant lesion?
Histologic features
The question, "Is there a premalignant lesion that pre-
cedes the development of epithelial ovarian cancer", has
been addressed through four approaches: (a) comparison
of the concordance of ovarian aberrations between
monozygotic twins where one had ovarian cancer; (b)
identifying preneoplastic changes in normal ovaries con-
tralateral to unilateral ovarian cancer; (c) evaluating archi-
tectural and cytologic changes of OSE adjacent to
epithelial ovarian cancer; and (d) comparing the pheno-
type of overtly normal ovaries, prophylactically removed
from cancer-prone women with an inherited predisposi-
tion for ovarian cancer, to normal ovaries from women of
the general population. The first clue to the clincopatho-
logical evidence was provided by Gusberg and Deligdisch
(1984), who examined the grossly normal ovaries that
were prophylactically removed from identical twin sisters
of patients with invasive carcinoma of the ovary [10]. Sur-
face papillations, inclusion cysts, nuclear polymorphism
or stratification in surface and invaginated epithelial lin-
ing are frequently found in these ovaries. All of these char-
acteristics have been postulated by various investigators to
be potentially premalignant histologic features. Other ear-
lier studies using both light microscopy and image cytom-
etry have reported similar cellular and nuclear atypia in
the non-cancerous OSE or cyst epithelium adjacent to pri-
mary ovarian tumors [11,12].
Ovaries from BRCA mutation carriers provide an excellent
opportunity to identify candidate lesions for the study of
early molecular changes in ovarian carcinogenesis,
because these women are at a significant risk for develop-
ing ovarian cancer compared to women without such a
Table 1: Histopathologic alterations of ovaries from women with family history of ovarian cancer
Present Absent
Histologic
Metaplasia of surface epithelium [13] [14–17]
Papillomatosis
Stratification
Epithelial inclusion cysts
Invaginations
Stromal hyperplasia [13] [14,15]
Cytologic
Nuclei of the surface epithelium [14,16,18]
Larger nuclei
Irregular contours
Heterogenous dense chromatin
Molecular
Increased expression of p53, c-erbB and Ki-67 [15,19]Page 2 of 8
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blinded study of 20 high-risk individuals and 20 women
with no family history of ovarian cancer, revealed a higher
rate of potentially preneoplastic features such as surface
papillomatosis, surface epithelial stratification, epithelial
inclusion cysts, invaginations and ovarian stromal hyper-
plasia in prophylactically removed ovaries from high-risk
individuals [13]. Although only 9 of the 20 women stud-
ied by Salazar et al. (1996) have documented germline
BRCA1 mutations, the study provides us with valuable
information on phenotypic alterations in ovarian tissues
due to hereditary influences. The positive family history of
breast/ovarian cancer strongly suggests that most if not all
of these women carry mutations in the BRCA1 or BRCA2
genes, even though they are not tested. The study also
identified two unanticipated microscopic ovarian neo-
plasms in these high-risk ovaries. Consistent with these
data, Werness et al. (1999) reported an increased fre-
quency of inclusion cysts in a blinded study of 64 prophy-
lactic oophorectomy specimens removed from women
with a strong family history of ovarian cancer compared to
30 controls [14]. In contrast, 3 blinded studies on prophy-
lactically removed ovaries from BRCA1 and BRCA2 muta-
tion carriers found no significant difference in these early
morphologic features related to ovarian carcinogenesis
[15–17]. On the other hand, the blinded histopathologic
analysis of Werness et al. (1999) revealed an important
finding: although no microscopic (pre)malignant features
such as papillomatosis and increased stromal activities
were found, image analysis identified changes in the
nuclei, where those from the ovaries of high-risk individ-
uals were larger, of irregular contours, and contained
more heterogeneously dense chromatin than nuclei of
control ovaries [14]. Similarly, precancerous changes in
the nuclei of high-risk ovaries were demonstrated by a
novel computational analysis in the study of Deligdisch et
al. (1999), which focused on BRCA founder mutations in
Jewish patients [18]. 77.6% of ovaries removed from
women of Ashkenazi Jewish descent who are at high risk
for ovarian cancer because of the prevalence of BRCA1
mutations showed significantly larger nuclei and non-
homogenous chromatin distribution than in control ova-
ries. Similar nuclear atypia was also identified in the non-
cancerous surface epithelium adjacent to primary ovarian
tumors compared to OSE from control ovaries [12]. How-
ever, there is no evidence of premalignant alterations in
tumor suppressor proteins and oncogenes, such as the
p53 tumor suppressor protein and the c-erbB2 oncopro-
tein, which are most frequently implicated in ovarian car-
cinogenesis, between OSE or cyst epithelium of ovaries
from women with inherited BRCA1 mutations and con-
trols. Neither was there a difference in cell proliferation
and apoptosis [15,19].
It is noteworthy that surface invaginations and inclusion
cysts are more frequent in high-risk ovaries than in control
ovaries. This is an exciting prospect because the ovarian
surface epithelium (OSE) is normally separated from the
ovarian stroma by the tunica albuginea, and the entrap-
ment of the OSE cells within the stroma to form inclusion
cysts generates a microenvironment in which the OSE is in
close proximity to the paracrine influence of adjacent
ovarian cortical stroma. Such epithelial-stromal interac-
tion is important for epithelial differentiation, and may
account for the Mullerian metaplasia commonly seen in
the inclusion cysts. This hypothesis is supported by the
observation that tubal epithelial metaplasia was fre-
quently present in inclusion cysts of ovaries contralateral
to ovaries containing unilateral carcinomas compared to
control ovaries [20,21]. It has been postulated that meta-
plastic and dysplastic changes of cyst-lining OSE cells
could also be promoted by increased levels of estrogen,
growth factors and bioactive cytokines in cyst fluid.
In culture
It is interesting that OSE of women with strong family his-
tories of breast and ovarian cancer differs not only geneti-
cally but also phenotypically from OSE of women with no
such family history (Table 2). Normal OSE is a mesothe-
lium of an uncommitted phenotype. It is a simple squa-
mous-to-cuboidal epithelium in vivo. In tissue culture,
normal OSE cells are highly responsive to environmental
signals and have a tendency to undergo epithelio-mesen-
chymal conversion over time. In contrast to OSE cells
from women in the general population (NFH-OSE) that
become mesenchymal after a few passages, OSE cells from
women with strong family history of breast/ovarian can-
cer (FH-OSE) retain predominantly epithelial morpholo-
gies and growth patterns. Furthermore, FH-OSE cells are
unable to contract three-dimensional sponge matrices,
suggesting that these cells are more committed to epithe-
lial differentiation and less responsive to wound-healing
stimuli such as those associated with ovulation [22]. The
ovarian carcinoma cell lines show an even more commit-
ted epithelial phenotype. Another (pre)neoplastic charac-
teristic of FH-OSE in culture is to form colonies with
whorls of elongated, irregularly shaped overlapping cells
in primary culture, which appear to be metaplastic [23].
These altered morphologic features are concomitant with
inappropriate expression of epithelial differentiation
markers. FH-OSE cultures contained more cytokeratin
and less mesenchymal collagen type III than NFH-OSE
[22]. Two of the more important indications to suggest an
increased commitment to an epithelial phenotype in
overtly normal OSE cells from women with family histo-
ries of ovarian cancer (FH-OSE) is the enhanced expres-
sion of CA125 [24] and E-cadherin [25]. CA125 and E-
cadherin are epithelial differentiation markers, whichPage 3 of 8
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are prominent in ovarian epithelial-lined clefts and
inclusion cysts, Mullerian epithelia, for example oviductal
and endometrial epithelia, and in ovarian carcinomas.
The high intensity and number of cells expressing both
markers also relate to the embryonic proximity of OSE to
Mullerian duct epithelia. The malignant tumors often
have histologic features that are reminiscent of the archi-
tecture and function of epithelia of the oviduct,
endometrium and endocerix. It is interesting that the dis-
tributions of E-cadherin and CA125 in culture were simi-
lar, although there is no evidence that the functions of
these two cellular components are related.
While the presence of hormone and growth factor recep-
tors of OSE and their ability to secrete cytokines and
growth factors is an integral part in normal OSE physiol-
ogy, the cells appear to become less responsive to environ-
mental signals and engaged into dysregulated autocrine
loops with malignant progression. For example, macro-
phage-colony stimulating factor (M-CSF) is secreted by
normal OSE cells and acts in a paracrine manner but
become an autocrine regulatory factor in ovarian cancer
cells, which also express its receptor [26,27]. Importantly,
FH-OSE cells produce hepatocyte growth factor (HGF)
which acts as an autocrine growth regulator in other ovar-
ian carcinoma cell lines, but rarely by normal OSE (9%).
61% of FH-OSE cultures express HGF and Met receptor
concomitantly [28]. Several signaling molecules, includ-
ing those of the phosphoinositol-3-kinase pathway are
already activated in FH-OSE cultures independent of
exogenous growth factor stimulation, which could be
attributed to the autocrine HGF-Met regulation in these
cells or other cytokines and growth factors. It is also pos-
sible that the PI3KCA gene which could lead to increased
phosphoinositol-3-kinase activity is already amplified in
FH-OSE cells [29], similar to the amplification of this gene
in many ovarian cancers [30].
Perhaps one of the most interesting observations in these
studies is that FH-OSE has a more limited growth poten-
tial and tends to senescence earlier than NFH-OSE in cul-
ture. This appears at a first glance to be different from the
increased cell growth that confers tumorigenesis, but is
particularly relevant to the paradoxical acquisition of
Mullerian epithelial differentiation in early stages of ovar-
ian neoplastic progression. As discussed earlier, most FH-
OSE cultures have a propensity to undergo metaplasia to
a Mullerian phenotype under physiological conditions,
however routine culture condition does not support
expansion of these transformed characteristics. Thus, the
differentiated, metaplastic surface epithelium tends to
senescence earlier in culture. Alternatively, the metaplastic
phenotype may be reversible and is lost in culture,
because causative factors, present in vivo, are missing. A
shorter telomeric length of FH-OSE than NFH-OSE cells
may provide an alternative explanation to the reduced
growth potential in these cells [31]. Loss of telomere pro-
tection which represents a greater proximity to cell senes-
cence and a decrease in genomic stability could contribute
to the earlier age of onset of ovarian cancer in women with
familial ovarian cancer syndromes.
Although the populations chosen for comparative studies
are likely to represent cancer-prone and non cancer-prone
groups have some limitations. First, it is difficult to accu-
rately define the risk of ovarian cancer. Women in the gen-
eral population who are carriers of BRCA mutations may
be at a greater risk for ovarian cancer due to genetic rea-
sons, however this does not account for other known non-
genetic factors such as reproductive history and use of oral
contraceptives. Similarly, the control population may not
be a pure low-risk population, since in most studies nei-
ther extensive family history analysis nor BRCA1 testing
has been performed on these women. Second, it is diffi-
cult to control statistically for age differences between the
high-risk cases and controls. Because familial ovarian
Table 2: Phenotypic differences of NFH-OSE and FH-OSE in culture
NFH-OSE FH-OSE
Response to environmental signals greater lesser
Growth potential greater lesser
Telomeric length longer shorter
Metaplastic colonies in primary culture rare frequent
Expression of
CA125 rare prominent
E-cadherin rare prominent
High molecular weight keratin less more
Collagen III more less
Coexpression of HGF and Met receptor rare frequent
Signaling pathways (such as PI3K) non-activated activatedPage 4 of 8
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cancer, women who decide to have their ovaries removed
prophylactically to prevent the development of ovarian
cancer are typically young, usually before age 45 as soon
as childbearing is completed. Ovaries are very rarely
removed from women at this young age under any other
circumstances.
BRCA-associated ovarian tumors
Many studies have sought to determine potential serum
biomarkers by comparing expression patterns of ovarian
carcinomas and normal human OSE cells using high-
throughput genomic and proteomic technologies [32,33].
Important to this review, Jazaeri et al. (2002) used micro-
array technology to examine the role of mutations in the
BRCA1 and BRCA2 genes in ovarian carcinogenesis by
comparing gene expression patterns in ovarian cancers
that are associated with germline BRCA1 and BRCA2
mutations and sporadic ovarian cancers [34]. Interest-
ingly, BRCA1 and BRCA2-associated ovarian tumors dis-
play distinct gene expression profiles. 110 genes showed
statistically significant different expression levels. This
result suggests that BRCA1 and BRCA2 have different
functions in ovarian carcinogenesis even though both
proteins have been implicated in DNA damage repair,
chromatin remodeling and transcriptional regulation.
These data are in agreement with a previous study illus-
trating differences in gene expression profiles in BRCA1
and BRCA2-linked breast cancer [35]. The second impor-
tant finding is that the molecular profiles of hereditary
and sporadic ovarian cancers are not significantly differ-
ent; sporadic ovarian tumors shared gene expression fea-
tures of either the BRCA1 or BRCA2-associated tumors.
The parallels in hereditary and sporadic ovarian tumor
phenotypes suggest that sporadic tumors may also result
from epigenetic loss of BRCA functions through inactiva-
tion of the BRCA1 or BRCA2 genes. Although mutations
of BRCA genes are rare in sporadic ovarian tumors, loss of
BRCA function through high rates of loss of heterozygos-
ity, hypermethylation of the BRCA promoter or other
mechanisms is a frequent event in sporadic ovarian
tumors [36]. These alternate pathways may play a role in
the loss of function of BRCA1 or BRCA2 which is required
for the disease phenotype to develop. Consistently,
decreased expression of BRCA1 in the nucleus is observed
in sporadic ovarian tumors, suggesting defects in normal
nuclear function of this protein [37,38]. It is also possible
that the molecular mechanisms in sporadic tumors are
altered in a similar way as in BRCA-associated ovarian
tumors. It has been suggested that there are other overrid-
ing key pathways driving ovarian cancers, which are as yet
undescribed [39]. Although the clinical and pathological
features of ovarian cancers in women with inherited germ-
line BRCA1 and BRCA2 mutations compared to ovarian
cancers that arise sporadically have been less consistent
[40], ovarian cancers arising from BRCA1 or BRCA2 muta-
tion-positive families are more likely to be invasive, high
grade and of serous histologic type than cancers arising in
women without BRCA mutations [40,41].
Is the relative risk for ovarian cancer associated 
with the location of BRCA mutations?
Although there is little evidence for mutational hotspots
or clustering on BRCA1 and BRCA2 genes except in certain
populations, e.g. Ashkenazi Jewish, a defined repertoire of
mutations have been detected, it has been suggested that
the location of BRCA mutations is associated with differ-
ent ovarian cancer risk. Mutations at the C-terminal of
BRCA1 protein appear to be associated with breast cancer,
whereas mutations at the N-terminal of the protein are
more strongly associated with ovarian cancer [42]. The
RING-finger domain of the N-terminus of BRCA1 protein
appears to play a role in the anti-apoptotic function in
OSE cells [43]. Among BRCA2 mutation carriers, the risk
of ovarian cancer is greatest for women with mutations
clustered in a region of 3.3 kb in exon 11 [44]. However,
other genetic and environmental factors are also impor-
tant. For example, rare alleles of HRAS1 have been shown
to increase the risk for ovarian cancer at least two times in
women with the same BRCA1 mutation [45]. Rare HRAS1
alleles also contribute to a greater risk of ovarian cancer in
the general population [46]. Preliminary data suggest that
the 17β-hydroxysteroid dehydrogenase-2 gene may func-
tion as a linked modifier of ovarian cancer risk in BRCA1
mutation carriers [47].
The nature of germline BRCA1 and BRCA2 mutations are
to some extent dependent on the ethnicity of the popula-
tion [see review in [48]]. The most notable example of
mutations in these genes is the Ashkenazi Jewish women
with early-onset ovarian cancer (and breast cancer), where
two specific mutations in BRCA1 (185del AG and
538insC) and one mutation in BRCA2 (6174delT) appear
to be particularly common. While another BRCA2
999del5 mutation is more common to the Icelandic pop-
ulation and a unique BRCA1 mutation (3452delA) was
identified in two women diagnosed with ovarian cancer
from Mongolia, a geographically isolated population.
Gender and tissue-specific properties
Although germline BRCA1 or BRCA2 mutations are
present in all tissues and BRCA proteins exhibit funda-
mental cellular functions in maintaining genomic integ-
rity, mutations in BRCA strongly predispose for breast and
ovarian cancers in women. There are two possible hypoth-
eses to explain why mutations in BRCA1 and BRCA2 lead
specifically to breast and ovarian cancer: first, the loss of a
second allele of BRCA preferentially occurs in women, in
whom breast and ovarian tissues are preferred sites, but
what causes this preferential loss is not known. Second,Page 5 of 8
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effect on hormone functions, may favor transformation in
hormone-responsive epithelial tissues. Beginning in
puberty, both the breast and ovarian epithelium prolifer-
ate rapidly in response to changes in levels of estrogen.
Reproductive factors linked to estrogen, such as oral con-
traceptive use, are associated with breast and ovarian can-
cer risk.
A recent study by Ganesan et al. (2002) may provide some
insights to the question of why BRCA1 mutation is a pre-
disposing factor for hereditary cancer syndromes more
frequently in women than in men. BRCA1 is found to
contribute to the X-chromosome inactivation, which is a
process specific to female cells [49]. Moreover, breast and
ovarian carcinoma cells lacking BRCA1 show evidence of
defects in X-chromatin structure. Such defects could be
reversed by the expression of wild-type BRCA1 [49]. In
support of this model, a preliminary study suggests that X-
inactivation may not be a random process in women with
BRCA1 mutations. Interestingly, the process is in some
ways favorably occurring on the alternative X-chromo-
some carrying the wild-type BRCA1 allele [50]. This sug-
gests that the combination of a germline mutation of the
BRCA1 gene as well as nonrandom X-chromosome inacti-
vation could eliminate wild-type activity of this gene and
thus contributes to the increased incidence of cancer in
these females. However, further experiments will be
required to verify this issue. It is also intriguing to ask
whether such properties could be related to the abnormal
nuclear structure seen in high-risk ovaries described ear-
lier in this review [14,18].
BRCA1 has been reported to interact with the estrogen
receptor (ER) and inhibit both ligand-dependent and -
independent ER activation [51,52]. Estrogen is a principal
determinant in the epithelial cell proliferation, differenti-
ation and normal functional status of breast and ovary,
which are both estrogen-responsive organs. Therefore,
BRCA1 mutations might possibly promote the growth
and differentiation of ovarian and mammary epithelial
cells through regulation of estrogen receptor activity, and
by implication, contribute to the initiation of ovarian and
breast cancer. However, it seems confusing that BRCA1
mutations have never been linked to tumors of other
estrogen-responsive tissues, including the endometrium.
Alternatively, not mutually exclusive with the model
described above, certain oxidative forms of estrogen have
been reported to be genotoxic [53], and BRCA1 has been
proposed to play a role in protecting breast and ovarian
tissue from estrogen-induced DNA damage. BRCA1 has
also been documented to enhance androgen-dependent
transactivation by androgen receptor [54], allelic variants
of which could modify breast or ovarian cancer pene-
trance in BRCA1 mutation carriers [47,55].
BRCA1-/- mouse embryos exhibit early embryonic
lethality, which hinders the study of the tumor suppres-
sion activity of BRCA1 [56]. Mice heterozygous for muta-
tions in either the BRCA1 or BRCA2 gene have been
generated. Although these mice are not predisposed to
mammary or ovarian tumor development, they display
defects in mammary duct branching and atrophic ovaries
with significantly arrested follicular development in
response to estrogen [57]. The incidence of breast tumors
increases when the mice were crossed into a p53+/- back-
ground [58], consistent with the idea that loss of BRCA
gene alone is not sufficient to confer tumor formation and
requires the accumulation of addition mutations in genes
for checkpoint controls, including the inactivation of p53.
Conclusion
One reason for the high mortality of ovarian cancer is that
almost 70% of the disease is diagnosed at a late stage
when disease has spread beyond pelvis. However, if a
woman is diagnosed with an early stage (stage I) ovarian
cancer, the survival rate is close to 90% without altering
current therapeutic approaches. Data presented in this
review suggest that ovaries removed prophylactically from
women with familial ovarian cancer syndromes may
appear macroscopically normal; however, a careful his-
topathological examination may reveal a number of can-
cer-prone phenotypes and perhaps even unanticipated
malignant neoplasms. The identification of early molecu-
lar changes in OSE cells of ovaries from women with
familial ovarian cancer is encouraging, as this contributes
to our understanding about the biology of ovarian tissue
in women at increased risk of developing ovarian cancer,
which to date is still largely unknown. Such knowledge
may help in the development of possible screening tools
for high-risk women to better define their risk of develop-
ing ovarian carcinomas and the management of the
disease.
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